← All trials
NCT05490043
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 30, 2022
- Primary completion
- Aug 15, 2024
- Completion date
- Dec 30, 2024
- First posted
- Aug 5, 2022
- Last posted
- Oct 28, 2022
- Enrollment
- 62
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Antengene CorporationLead sponsor
- InnovadermStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.